OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
22/11/2025
Voltar para busca
Dado oficial do USPTO
PR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 35, 40, 42
Data de depósito
18/03/2024
Data de registro
11/03/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/03/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
24
Localização do titular
SG
Examinador
SEVERSON, JUSTIN
Unidade examinadora
M20
Localização atual
GENERIC WEB UPDATE
Descrição da marca
The mark consists of a shaded circle with the letters "PR" in the center in stylized outline font. The letter "P" is above and to the left of the letter "R".
Titulares e representantes
Titulares
PharmaGend Global Medical Services Pte Ltd
Representantes
Esther Kim
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Bases being chemical preparations of pharmaceutical drug product formulationmanufacturingpackingtesting and release to market; salts being chemical preparations for improved therapeutic actionsadditional indicationdrug product stability enhancement and bioavailability improvement in pharmaceutical products; cellulose derivatives being chemical preparations for use as excipients in drug formulationproviding controlled release and delayed release of drug enhancing bioavailability of drug product; chemical preparations for scientific purposesother than for medical or veterinary use; chemical substances for analyses in laboratoriesother than for medical or veterinary purposes; animal extracts in the nature of from bovine source for use in pharmaceutical and nutraceutical manufacturingparticularly in dietary supplements and therapeutic drug products as well as nutritional products for the food industry; biological preparations for use in industry and scienceother than for medical or veterinary purposes; diagnostic preparationsother than for medical or veterinary purposes; plant extractsother than essential oilsfor use in the manufacture of pharmaceuticals; plant extractsother than essential oilsfor use in the manufacture of cosmetics
Classe 5
Immunological products for intravenous injectionsnamely for immune system supportsuch as vaccinesmonoclonal antibodies (mAbs)Cytokines/Cytokine Inhibitors; tablets for medicinesspecifically diureticanti-fungaldigestive disordersanti-inflammatoryantidiabeticdementia tablets for treating common infections and chronic diseases; drinking water fused with electrolytessaltshemodialysis solutionsuitable for rehydration and maintenance therapy for medical purposes; gelatin capsules sold empty for pharmaceuticals; slimming pills; medicinal ointments for treating skin conditionssuch as dermatitiswoundsburnsoffering antiseptic and healing properties; medicines for human purposes for treating various ailments ranging from cough and cold medicines to cardiac disease; Nutraceutical preparations for therapeutic or medical purposes for treating digestive disordersvitamin deficiencytherapeutic dosage of Vitamins; biochemical medicines for treating metabolic disordershormonal imbalancesautoimmune diseasesrare genetic conditionssuch as enzyme replacement therapiespeptide-based drugsnucleotide-based therapies; pharmaceutical preparations for treating heart diseasesasthmaobesitydiabeteshypertension
Classe 35
Import-export agency services; business management consultancy; outsourcing services; business research; wholesale store services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies; retail store services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies
Classe 40
Custom assembling of materials for othersmulti-layer coated tabletsliquid filled hard gelatin capsulesbottle filling activities; providing information relating to material treatment; processing of metal surfaces using precision grinding techniques; irradiation of food; cryopreservation services; food and drink processing for others; processing of chemicals; sorting of waste and recyclable material; bookbinding; grinding
Classe 42
Technological research in the field of formulation developmentscale-up batchesformulation refinementdrug delivery systemsoptimization of production processes; conducting technical project studiesbioequivalence studiesclinical trial study design and regulatory compliance research in the pharmaceutical field; scientific laboratory services; providing scientific informationadvice and consultancy relating to carbon offsetting; quality control for others; industrial inspection serialization of productsmedical devices; quality assessment of pharmaceutical manufacturing processesprocess validationfocusing on batch consistencycontamination controlimpurity profiling and GMP compliance; biological research; Medical and scientific researchconducting clinical trials for others; medical research
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/11/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/11/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/10/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/09/2025
FIMP
FINAL DISPOSITION PROCESSED
24/09/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/06/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/03/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
11/03/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/01/2025
PUBO
PUBLISHED FOR OPPOSITION
21/01/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/01/2025
ISCR
WITHDRAWN FROM ISSUE - OG REVIEW QUERY
10/01/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2024
RFNT
REFUSAL PROCESSED BY IB
19/10/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/10/2024
RFRR
REFUSAL PROCESSED BY MPU
02/10/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/09/2024
CNRT
NON-FINAL ACTION WRITTEN
26/09/2024
DOCK
ASSIGNED TO EXAMINER
25/09/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/06/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/06/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/06/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.